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Background: Prophylactic strategies are urgently needed for prevention of severe inflammatory responses to
respiratory viral infections. Bacterial-host interactions may modify the immune response to viral infections.
Methods: We examined the contribution of Intranasal administration of two different Bifidobacterium longum
strains or its isolated cell wall in controlling viral induced inflammation using a murine model of influenza
infection. We monitored mortality and morbidity over a 10-day period and viral load, differential broncho
alveolar lavage (BAL) fluid inflammatory cell counts, Lung tissue histology, BAL and serum cytokines, markers
of vascular damage and cell death were quantified.
Findings: Intranasal administration of Bifidobacterium longum 35624 or its isolated cell wall prior to virus
inoculation significantly reduced viral load within the lungs and significantly improved survival. Reduced
viral load was associated with reduced lung injury as suggested by cell death and vascular leakage markers, a
shift from neutrophil to macrophage recruitment, reduced inflammatory cytokine levels (including IL-6),
reduced type 1 and 2 interferon levels, but increased levels of interferon-λ and surfactant protein D. These
protective effects were maintained when the bifidobacterial cell wall preparation was administered 24 h
after viral inoculation. The protective effects were also observed for the Bifidobacterium longum PB-VIRTM
strain.
Interpretation: Exposure to these bifidobacterial strains protect against the inflammatory sequelae and dam-
age associated with uncontrolled viral replication within the lung.
Funding: This work has been funded, in part, by a research grant from GlaxoSmithKline, PrecisionBiotics
Group Ltd., Swiss National Science Foundation grants (project numbers CRSII3_154488, 310030_144219,
310030_127356 and 310030_144219) and Christine K€uhne  Center for Allergy Research and Education
(CK-CARE).
© 2020 PrecisionBiotics Group Ltd. Published by Elsevier B.V. This is an open access article under the CC BY-
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Respiratory viral infections are common but are usually success-
fully cleared by an appropriate host immune response. A minority of
individuals with pre-existing lung disease, other co-morbidities and
the elderly are susceptible to severe disease or secondary infections.
An important contributor to mortality in vulnerable individuals isacute respiratory distress syndrome (ARDS) which appears to be due
to an exaggerated or dysregulated immune response to a certain viral
infections including influenza infection [1]. Unfortunately, a predic-
tive biomarker for those likely to experience mild versus life-threat-
ening disease in response to the same virus is not yet available. In the
interim, an alternative or complementary approach may be to mobi-
lise the upper respiratory tract immune system via modifications of
the local microbial ecosystem.
Accumulating evidence suggests that indigenous bacteria or their
components may have distinct effects on mucosal immunity, varying
Research in Context
Evidence before this study
Influenza is an acute respiratory infection caused by influenza
viruses, which are highly transmissible and pose a significant
threat to public health, causing up to 650,000 deaths world-
wide each year. The appropriate host immune response to the
virus is critical to control viral replication and avoid immune-
mediated tissue destruction. The composition of the micro-
biome significantly modifies host immune responses and accu-
mulating evidence suggests that the intestinal microbiota and
certain microbial strains can influence the immune response to
influenza infection. Prophylactic exposure to specific microbes
for several weeks can induce IFN-g or the type 1 interferons
(IFN’s), which are believed to promote an anti-viral response
prior to influenza exposure.
Added value of this study
We demonstrate that intranasal administration of specific Bifi-
dobacterium longum strains or an isolated cell wall fraction, are
protective in a murine model of lethal influenza infection. Long
term prophylactic exposure was not required for protection as
intranasal administration remained effective even if initiated
24 h after influenza virus inoculation. Bacterial cell wall expo-
sure induced an early interferon lambda and surfactant protein
D response that correlated with reduced viral titres and
reduced IFN-g and type 1 IFN’s levels within the lung. Improved
survival was associated with reduced proinflammatory cyto-
kines, reduced neutrophils, reduced cell death and vascular
injury markers in bronchoalveolar lavages. This study identifies
a novel mechanism whereby a protective factor within the B.
longum cell wall promotes appropriate type III interferons and
surfactant protein D responses for anti-viral defense, while
reducing type I IFN responses.
Implications of all the available evidence
This study adds to a growing body of evidence that links suc-
cessful anti-viral immune responses with the bacteria micro-
biota. Intact viable bacterial cells might not be required as
isolated components can replicate the immunological effects.
The overall implication of these studies is that intra-nasal
administration of specific microbial components (e.g. from the
B. longum cell wall) can be safely utilised during the influenza
season to protect those individuals at high risk of poor out-
comes to respiratory infection, including the elderly, obese,
asthmatics and patients with COPD.
2 D. Groeger et al. / EBioMedicine 60 (2020) 102981from immunomodulatory or immunostimulatory properties depend-
ing on the individual strain and environment [24]. The immune
response to commensal microbes is not simply a form of host defense
but represents an intimate and sophisticated bidirectional communi-
cations platform that ensures a stable microenvironment is main-
tained with important symbiotic physiological effects on the host. An
effective immune response is one that effectively reduces the viral
load, with limited collateral damage to lung tissue, and without an
excessive or aberrant inflammatory reaction. Exposure of respiratory
immune cells to specific microbiota-associated regulatory signals
may dampen the aberrant inflammatory response and support effi-
cient clearance of the virus [5-8].
One immunoregulatory microbe is the B. longum 35624 strain,
which has been shown to mitigate pro-inflammatory responses to
bacterial infection by induction of tolerogenic immune responseswithin the gastrointestinal tract in murine and human studies [9-12].
Some, but not all, of these immunoregulatory properties have been
attributed to an exopolysaccharide (EPS) which may dampen inflam-
matory responses in the lung and limit allergen-induced eosinophil
infiltration [13-15]. While bifidobacteria are usually associated with
the gastrointestinal tract, immunomodulatory metabolites or bifido-
bacterial cell wall components are likely to engage the immune sys-
tem, regardless of the mucosal site to which they are exposed.
We have assessed the B. longum 35624 strain and its isolated cell
wall for protective effects in vivo in a murine model of lethal influ-
enza infection. The results show that intra-nasal administration
reduces viral replication in the lung, protects against lung damage
and enhances survival. These effects are associated with an inter-
feron-λ and surfactant protein D response.
2. Materials and methods
2.1. Mice and infection model
Female 7-week-old BALB/c mice (Specified Pathogen Free; SPF)
were purchased from Charles River Laboratories (l' Arbresle Cedex,
France). All mice were housed in Preclin Biosystems AG (Epalinges,
Switzerland). Mice were randomly allocated to 5 animals per cage in
individually ventilated cages in a 12/12 h light/dark cycle with food
and water available ad libitum and cage enrichment was present.
Mice were monitored daily and acclimatized to facility for 7 days
prior to initiation of study (Study Day 0). Daily care of the animals
was performed. 8-week-old female mice were used for all experi-
ments. Mice from the same litter and co-housed were randomly allo-
cated to different treatment groups prior to start of experiment, to
avoid subjective bias of allocating mice into treatment groups after
symptom onset. Investigators were blinded to the identity of the
treatment groups until data analysis. Influenza virus strain PR8 (A/
Puerto Rico8/34, H1N1) was obtained from Virpur (San Diego, CA).
The initial PR8 stock concentration was (1 £ 10e8 pfu/ml) and it was
stored frozen in aliquots. When required these aliquots were thawed
and diluted in phosphate-buffered saline (PBS) to 100 PFU/50 ml
which was then administered intranasally to the mice for all viral
infection experiments. For the viral challenge the mice were anaes-
thetized by intraperitoneal injection with 9.75 mg Xylasol and
48.75 mg Ketasol per kg body weight and each animal received 50 ml
virus solution by intranasal inoculation. All animal experiments were
approved by and performed in strict accordance of the Institutional
Ethics Committee of Animal Care of Preclin Biosystems AG (Epalinges,
Switzerland) and the GSK Policy on the Care, Welfare and Treatment
of Animal. These experiments were approved under the local authori-
zation license number VD2830 (issued and approved by: Service de la
consommation et des affaires veterinaires du Canton de Vaud).
2.2. Bacterial cultures
A glycerol stock culture of B. longum 35624 was provided by Pre-
cisionBiotics Limited. It was thawed and inoculated into 10 ml of de
Man Rogosa and Sharpe medium (MRS; Oxoid Ltd., Basingstoke,
Hampshire, United Kingdom) supplemented with 0.05% cysteine-HCl
and incubated for 24 h at 37 °C under anaerobic conditions. This was
then inoculated into 50 ml of broth, and after 24 h then inoculated
into 250 ml for a further 48 h. Freeze dried B. longum 35624 strain
and B. longum PB-VIRTM strain were supplied by PrecisionBiotics
Limited.
2.3. B. longum 35624 cell wall fraction
The bacterial cell wall (CW) were prepared as described briefly
below. The cells (total cell count1.5 £ 1011) were centrifuged at
14,000 rpm, with the JA-20 rotor (Avanti J-26 x P Beckman Coulter)
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phosphate buffered saline (PBS) pH 7.0. The pelleted cells were resus-
pended in 50 ml of PBS and were incubated with a chelating agent
EDTA (final concentration 5 mM) (Fluka) followed by two freeze
thaw cycles in liquid nitrogen. The cells were subjected to enzymatic
treatment with a glycoside hydrolase lysozyme (Sigma 10 mg/ml)
and/ or N acetylmuramidase mutanolysin (Sigma 2.5KU) for 1 hour at
37 °C with occasional agitation by vortexing. Finally, the cells were
disrupted using a Sonicator (VibraCell SONICS) with sterile glass
beads (90150 mm particle size (VWR)) for 90 mins. Sonication
cycles were stopped when there was disruption to over 95% of the
cells as determined by microscopy. The beads were allowed to settle,
and after centrifugation at 14,000 rpm for 20 min, the supernatant
was removed. The cell wall fraction was removed from the top layer
of sediment and was further purified by 4 rounds of resuspension in
PBS and centrifugation at 14,000 rpm for 20 min. The final solution
was sterilized by filtration using 0.45 mm pore size filters (Millipore
Corp., Bedford, Mass.) and further purified by filtration using a
100 kDa MWCO UF device (Millipore Corp). The final dry weight of
the cell wall fraction was 30 mg/ml.
2.4. Bacterial treatments in the infection model
Mice were anesthetized using a calibrated vaporizer system
(VIP300, Provet, Vet.Med Center, Lyssach, CH) delivering the anes-
thetic agent, isofluoran (Provet AG,) into a plexiglas chamber contain-
ing the mice. Anesthetized animals were administered a total volume
of 50 ml of B. longum 35624 strain cells (109 total) or B. longum 35624
strain cell wall fraction (150 mg/ml or 7.5 mg/50 ml) or vehicle (PBS)
intranasally, as trickled over both nostrils using a 100 ul Gilson
pipette. In the dose response experiment, the B. longum 35624 strain
cell wall fraction was diluted from the highest dose of 7.5 mg/50 ml,
to 0.75 mg/50 ml, 0.25 mg/50 ml, 0.075 mg/50 ml and 0.0075 mg/
50 ml. This was administered at 2 h, +1 day, +3 days and +5 days
post viral inoculation on Day 0. Uninfected vehicle controls were
included by administering the vehicle control on day +1 and day +3,
but without the PR8 influenza intranasal inoculation. Uninfected and
untreated controls were included as the 0 days measurement. Endo-
toxin levels of the cell wall fraction were 0.6EU/ml (0.03EU per 50 ul)
as assessed by the PyroGene Recombinant Factor C Assay (Lonza).
Animals were monitored daily for morbidity (including tempera-
ture, and clinical score). Temperatures were recorded rectally utiliz-
ing a Microtherma 2 Type “T” Thermometer (TW2193). While the
Clinical Criteria were scored as follow:
1 point for a healthy mouse; 2 points for a mouse showing signs of
malaise, including slight piloerection, slightly changed gait and
increased ambulation; 3 points for a mouse showing signs of strong
piloerection, constricted abdomen, changed gait, periods of inactiv-
ity; 4 points for a mouse with enhanced characteristics of the previ-
ous group, but showing little activity and becoming moribund; 5
points for a deceased mouse. Mice were euthanized when they
reached clinical score greater than 4 or a temperature of less than
33 °C, whichever came first.
On Days 0, 3, 5 and 10 mice underwent bronchoalveolar lavage
(BAL) for BAL cytometry and for measurement of cytokines and
markers of cell death and vascular leakage. A subset of animals was
sacrificed on Days 0, 3, 5 and 10 for phlebotomy, organ removal and
analysis. Viral levels in lung tissue (half of all lung lobes) was quanti-
fied by quantitative PCR (qPCR). For a subset of animals, the collected
lung tissue (half lung lobes) was snap-frozen for histology and stored
frozen at 80 °C.
In specific experiments, the therapeutic effects of B. longum 35624
cell wall was determined by administration post-infection on day +1
and day +3. Uninfected Vehicle controls were included by administer-
ing the vehicle control on day +1 and day +3, but without the PR8
influenza intranasal inoculation. In some experiments, the efficacy ofanother B. longum strain, B. longum PB-VIRTM (109 total) was assessed
by administration at 2 h, +1day, +3days.
2.5. Measurement of viral levels in lung tissue
Total RNA was purified from isolated lung lobes using TRI Reagent
(Molecular Research centre) and then treated with DNase (Invitro-
gen) to avoid genomic DNA contamination. RNA was reverse tran-
scribed to cDNA using SuperScript III (Invitrogen). cDNA was
quantified by real-time PCR (iCycler; Bio-Rad) using SYBR Green
(Stratagene) and samples were normalized to GAPDH expression lev-
els. Primer sequences (forward and reverse, respectively) used were
influenza PR8 Matrix protein, 50-GGACTGCAGCGTAGACGCTT-30 and
50CATCCTGTATATGAGGCCCAT-30.
2.6. Broncho-alveolar lavage (BAL)
Broncho-alveolar lavage (BAL) was performed using 500 ul of PBS
supplemented with 0.2% BSA. Total cell numbers in the BAL were
determined using a Coulter Counter (IG Instrumenten-Gesellschaft
AG, Basel, Switzerland). Differential cell counts were performed on
cytospins stained with Diff-Quik solution (Dade Behring, Siemens
Healthcare Diagnostics, Deerfield, IL). Percentages of eosinophils,
neutrophils, macrophages and lymphocytes were determined by
counting 200 cells per sample.
2.7. Histology
Lung tissue was fixed in 10% neutral-buffered formaldehyde and
paraffin embedded under standard conditions. Tissue sections
(5mm) were stained with haematoxylin and eosin (H&E) with a stan-
dard protocol. Qualitative assessments were performed by a blinded
observer. Representative photomicrographs (600x) were taken to
illustrate the major distinguishing morphological features among the
experimental groups.
2.8. Measurements of cytokines and chemokines
The concentrations of murine IL-1b, IL-2, IL-4, IL-5, IL-6, IL-9, IL-
10, IL-12p70, IL-12/IL-23p40, IL-13, IL-15, IL-16, IL-17A, IL-17A/F, IL-
17C, IL-17E, IL-17F, IL-21, IL-22, IL-23, IL-30, IL-31, IL-33, IP-10,
MIP3a, MIP-2, MIP-1b, MIP-1a, MCP-1, KC/GRO, TNF-a, VEGF, EPO,
GM-CSF, IFN-g in both serum and BAL fluid were measured using a
U-PLEX Biomarker Group 1 Mouse 35-Plex kit (MesoScale Discovery)
following the manufacturers' instructions. ELISA kits were used to
measure levels of murine IL-28 (IFN-λ 2/3), G-CSF, TRAIL and AREG
(RayBiotech, Inc,), oncostatin M and surfactant protein D (SP-D) (R&D
Systems), IFN-a (ThermoFisher Scientific) and IFN-b (PBL Assay Sci-
ence).
2.9. Markers of lung injury
Vascular leakage into BAL fluid was assessed using a mouse serum
albumin ELISA Quantitation Set (Bethyl Laboratories, Inc., Montgom-
ery, TX). To measure cell death, lactate dehydrogenase (LDH) activity
was quantified using an LDH assay (Sigma-Aldrich). This assay was
performed in a 96-well plate for 30 min according to the manufac-
turer’s instructions and analyzed using the MicroTek plate reader
(Bio-Rad, Hercules, CA).
2.10. Statistical analysis
Graphing and statistical analysis were performed using Prism 8
(GraphPad software, San Diego, CA, USA). Treatment group sample
sizes were designed to give statistical power, while minimizing ani-
mal use. For in vivo experiments, treatment groups of n = 5 were
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viral load measurement, survival analysis, clinical score, and rectal
temperature to increase power. All the time course data was
expressed as the mean§ SEM or as box-and-whisker plots with the
median values and maximum/minimum values for day 5 analysis.
Survival differences were assessed by Log-rank (Mantel Cox). The dif-
ferences between two groups were analysed for significance using
the Mann-Whitney test. Intergroup differences were assessed by
one-way analysis of variance (ANOVA) followed by post hoc analysis
(Dunnett's multiple comparisons test). Time course differences
between 2 groups were assessed by two-way ANOVA followed by
post hoc analysis (Sidak’s multiple comparisons test. For overall daily
clinical and rectal temperature curves the p values were calculated
using area under the curve analysis with unpaired t-test with Welch’s
correction.
3. Results
3.1. Intranasal B. longum 35624 enhances survival in a murine
influenza model
The experimental outline is shown in a. Intranasal administration
of B. longum 35624 intact cells or the strain-derived cell wall fraction
prior to and after influenza inoculation reduced viral load in lung tis-
sue compared with controls (p<0.0001 n = 15 per group one-way
ANOVA) at 5 days post viral inoculation (Fig. 1b). The reduction in
viral load was associated with improved survival with 53% of the
mice who received the cell wall fraction surviving up to 10 days,
compared to 0% survival in control infected mice given vehicle alone
(p = 0.0011, n = 15 per group Mantel Cox test) (Fig. 1c). Improved sur-
vival of the cell wall fraction-treated versus intact cell-treated ani-
mals may be dose related or due to selective purification of
protective factors associated with the cell wall. Subsequent experi-
ments focused on animals treated with the cell wall. In agreement
with the beneficial effects of the cell wall fraction on survival there
was a significant improvement in both clinical score and rectal tem-
perature in later timepoints especially (supplementary Figure. 1a-b).
There was a time-dependent increase in viral load in vehicle control
infected animals, which was reduced at all time points in the cell
wall treated mice. (Fig. 1d). The reduction in viral load by the cell
wall fraction was dose-dependent (Fig. 1e).
To exclude the possibility that the survival benefit from intranasal
administration of the bifidobacterial strain or cell wall component
might be due to non-specific factors such as a change in the pH of the
nasal cavity, the cell wall was also administered +1- and +3-days
post-inoculation with the virus. The bacterial-derived cell wall treat-
ment administered post-virus inoculation conferred protection and
was associated with reduced viral loads at day 5 similar to the levels
observed in mice receiving the bifidobacterial cell wall prior to infec-
tion (supplementary Figure. 2). At day 9 post inoculation of the virus,
0 of 5 control animals had survived, while 3 of 5 animals in the group
administered the cell wall after virus infection had survived.
3.2. B. longum 35624 cell wall alters the cellular profile of BAL and
reduces lung injury
In addition to improved survival and reduced viral load, intra-
nasal administration of B. longum 35624 strain-derived cell wall was
also associated with a time-dependent alteration in the cellular pro-
file of immune cells within broncho alveolar lavages (BALs). A modest
increase in neutrophils was observed in both groups at day 3 post-
influenza inoculation, with a further significant increase in neutro-
phils observed in vehicle-treated animals at day 5, but not in the bac-
terial-derived cell wall treated mice (Fig. 2a). Macrophages,
eosinophils and lymphocytes increased in number at day 5, with
macrophages being the numerically dominant population by day 10in those mice that survived infection (Fig. 2a-d). Supplementary Table
1 illustrates neutrophil and macrophage numbers with 95% CI. In rep-
resentative lung tissue sections, the perivascular, peribronchial and
alveolar immune cell infiltrate was clearly observed in influenza
infected animals. An increase in neutrophils (red arrows) was partic-
ularly evident in vehicle control-treated animals while macrophages
(blue arrows) were present in B. longum 35624 cell wall treated ani-
mals (Fig. 3a-d). The impact of intra-nasal B. longum 35,624 strain-
derived cell wall on BAL cell phenotypes was dose-dependent (sup-
plementary Figure 3a-d).
Acute lung injury as shown by cell death and vascular leakage
associated with viral replication and inflammatory damage was
determined. Both lactate dehydrogenase (LDH) and albumin levels in
BAL were significantly increased following 5 days of viral infection
but were significantly reduced in the B. longum 35624 strain-derived
cell wall fraction treated animals (Fig. 4a-b). It is noteworthy that the
reduction in these markers was also observed in mice administered
the bifidobacterial cell wall preparation 1-day post-inoculation of the
virus in addition to those animals that were pre-treated with the cell
wall fraction (Fig. 4a-b).
3.3. B. longum 35624 cell wall exposure modifies cytokine
responses in the lung
The dynamic nature of the inflammatory response is reflected in
the differences in cytokines, chemokines and surfactant protein D
(SP-D) over the course of the infection (Figs. 5 and 6). Altered levels
of 42 cytokines and chemokines and SP-D were detected in the BAL
samples when measured at day 3 or day 5 virus post-inoculation.
These included the interferons (IFN-a, IFN-b, IFN-g , IFN-λ), chemo-
kines (KC/GRO, MIP3a, MCP-1. MIP-2, IP-10), hematopoietic growth
factors (GM-CSF, EPO) and cytokines (IL-4, IL-5, IL-6, IL-10, IL-12, IL-
30) (Figs. 5 and 6 (heatmap and representative graphs) and supple-
mentary Figure 3a-h). In particular, intra-nasal administration of the
bifidobacterial cell wall preparation was associated with an early pro-
tective interferon lambda (IFN-λ) and SP-D response at day 3 post-
infection in BALs with a reduction in the interferons (IFN-a, IFN-b,
IFN-g), cytokines and chemokines (IP-10, IL-6 and MCP-1) at day 5
post-infection when compared to the control (vehicle-treated) ani-
mals (Fig. 6a-h). A similar reduced level of cytokines and chemokines
was observed at day 5 for animals administered the isolated cell wall
1 day following inoculation with influenza virus (supplementary
Figure 4a-h).
Concurrent with the changes in BAL, serum levels of IFN-λ and SP-
D were increased, while serum IL-6 and IP-10 levels were decreased
at day 5 post-infection in mice pre-treated with the cell wall isolated
from B. longum 35624 in comparison with controls (supplementary
Figure 5a-h). The increase in SP-D serum levels was dose-dependent
and administration of the cell wall fraction 24 h after influenza inocu-
lation had a similar effect on serum SP-D levels (supplementary
Figure 6a-b).
3.4. Bifidobacterial-mediated protection is not restricted to B.
longum 35624
In order to determine if another B. longum strain might also
induce similar effects, we administered B. longum PB-VIRTM strain
using the same protocol as described above. This microbe also
improved murine survival, with 60% of recipients surviving compared
to 0% survival in control infected mice given vehicle alone (Fig. 7a)
(p = 0.0203 n = 5 per group Mantel Cox test). Improved survival in the
bifidobacterial-treated mice was associated with reduced viral loads
(p>0.001 n = 5 per group one way ANOVA) (Fig. 7b), an increase in
BAL macrophage counts (Fig. 7c), reduced BAL albumin, IFN-a and
IFN-b levels (Fig. 7d-f), and an increase in serum SP-D levels (Fig. 7g)
compared with the controls at 5 days post influenza inoculation.
Fig. 1. Intranasal B. longum 35624 protects against lethal influenza infection.
(a) Experimental model outline for infection with 100 plaque forming units (PFU) of strain A/PR8/34 H1N1 at time 0, following intranasal administration of B. longum 35624
bacterial cells, its isolated cell wall, or the vehicle control, at 2 h pre-infection and days 1, 3 and 5 post innoculation. (b) Viral load at day 5 post-innoculation in lung tissue as deter-
mined by quantitative real-time PCR (viral matrix protein normalized to b-actin expression). Data are presented as box-and-whisker plots with the median values and maximum/
minimum values illustrated of 5 animals per group. ****p < 0.0001 (1-way ANOVA). (c) Survival was monitored up to 10 days post-innoculation (n = 515 animals per group). ***p
< 0.001 (log-rank Mantel-Cox test). (d) Lung tissue viral load was determined at days 3, 5 and 10 post-innoculation. Data shown are mean § SEM results of 5 animals per group for
each time point. ****p < 0.0001 (2-way ANOVA). (e) Lung tissue viral load was determined at 5 days post-innoculation in animals administered different doses of isolated cell wall.
Data are presented as box-and-whisker plots with the median values and maximum/minimum values illustrated of 5 animals per group. ***p < 0.001; **p < 0.01 (1-way ANOVA).
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Fig. 2. B. longum 35624-derived cell wall alters cellular recruitment to the lungs.
Time-dependent changes in (a) neutrophil, (b) macrophage, (c) lymphocyte and (d) eosinophil levels in BAL fluid were influenced by viral infection and administration of bifi-
dobacterial cell wall fraction. Data shown are mean § SEM results of 5 animals per group for each time point. ***p < 0.001 (2-way ANOVA).
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The results show that an influenza infection that is uniformly
lethal in mice can be abated by intra-nasal administration of an intact
bacterial strain or an isolated cell-wall preparation of B. longum
35624. Enhanced survival was associated with reduced viral replica-
tion in the lungs, a dose-dependent reduction in markers of lung
damage, altered cellular infiltration and cytokines in BAL. Non-spe-
cific interference with the viral infection was excluded because pro-
tection was also evident when the bifidobacterial-derived cell wall
preparation was administered post-viral inoculation.
Influenza viruses are highly transmissible and effects on the host
can vary from mild symptoms to fatal disease. Despite over 100 years
of research, knowledge of the precise pathogenesis, optimal vaccines
and appropriate specific treatments remain elusive albeit with signif-
icant advances in oxygen therapy, mechanical ventilation, antivirals,
and antibiotics [16]. A successful antiviral response usually involves
rapid localised secretion of pro-inflammatory cytokines and interfer-
ons (IFNs) to limit viral replication accompanied by appropriate acti-
vation of NK cells, innate lymphoid cells (ILCs), neutrophils and
monocytes [17,18]. However, if this response is delayed or insuffi-
cient then sustained activation of these innate immune cells occurs
that can cause catastrophic damage within the lungs [18,19].
Resolution of virus-induced innate-mediated inflammation
requires migration of dendritic cells, macrophages and adaptive
immune cells to infected sites [19-21].
The murine model utilised in this report replicates these features
of influenza virus-induced immune pathology whereby viral load
increases dramatically within 5 days, which is associated with ele-
vated innate immune cells (especially neutrophils), cytokines, cell
death, vascular damage and ultimately leads to death [22]. Macro-
phages and lymphocytes dominated the lavages of mice in the B.longum cell wall treated group that survived up to 10 days following
infection.
The rationale for considering bifidobacteria as a strategy for host
defense against respiratory viral infections is primarily based on their
recorded modulatory effects on innate and acquired immunity in
humans and experimental animals [9-12,15,23]. While the majority
of human studies have been conducted following oral administration,
beneficial effects of probiotics in non-gastrointestinal infections have
also been observed [24]. Several bacterial strains have been con-
firmed to exert protective effects against influenza infection in
murine models after oral administration, including B. longum [25],
Lactobacillus casei [26], and Lactobacillus pentosus [27]. In addition,
nasal administration of viable or non-viable probiotics such as Lacto-
bacillus casei Shirota, Lactobacillus pentosus S-PT84 and Lactobacillus
rhamnosus GG/ CRL1505 can improve cellular responses against influ-
enza infection [28-31]. The responsible mechanisms were shown to
be associated with an increase in IFN-g or the type I IFNs [25,26,29-
37]. In contrast, we show that improved survival and reduced viral
titres are associated with decreased IFN-g and type I IFNs, suggesting
a novel mechanism of action.
The most well-defined antiviral responses include the type I IFNs,
IFN-a and IFN-b, but their pathologic potential has also been
observed, particularly in the setting of acute influenza infection [38].
Type I IFN-driven inflammatory features in patients with severe
influenza were recently documented leading to a proposal that the
type I IFN response can play a pivotal role in exacerbating inflamma-
tion [39]. In this context, it is noteworthy that the bifidobacterial-
mediated responses in the present study were associated with a sig-
nificant reduction in interferons a and b in BAL samples when com-
pared with controls. Similarly, reduced levels of the downstream
cytokines stimulated by type I IFNs, such as IL-6, IFN-g , and the che-
mokines IP-10 (also known as CXCL-10) and MCP-1 (CCL2) were
Fig. 3. Influenza infection and immune cell infiltration in lung tissue sections.
Selected photomicrographs (600x) of formalin-fixed, paraffin-embedded lung tissue sections stained with H&E from (a) animals receiving vehicle control alone at day 3 post-
influenza inoculation; (b) B. longum cell wall-treated animals at day 3 post-influenza inoculation; (c) animals receiving vehicle control alone at day 5 post-influenza inoculation; (d)
B. longum cell wall-treated animals at day 5 post-influenza inoculation. Neutrophils (red arrows) and macrophages (blue arrows) are identified in the selected photomicrographs.
Scale bar=40mM.
D. Groeger et al. / EBioMedicine 60 (2020) 102981 7observed. IL-6, IFN-g , IP-10 and MCP-1 have been shown to be ele-
vated in people infected with influenza [40-43]. In experimental
models, blockade of IFN-g and IP-10 with monoclonal antibodies
ameliorates virus-induced lung injury [44,45].
While the optimal immune response to respiratory viral infections
has yet to be defined, interferon-λ is known to participate in limiting
viral replication and tissue damage. Interferon-λ (also known as IFNls,
type III IFNs or IL-28 and IL-29) constitute a class of interferons shar-
ing homology, expression patterns, and antiviral functions with the
type I IFNs IFN-a and IFN-b [46,47]. Interferon-λ induces down-
stream signaling cascades similar to that of type I IFNs, driving the
expression of interferon-stimulated genes (ISGs) and the induction of
antiviral responses [48,49]. We observed that the levels of IFN-λwere
significantly increased in BAL samples of bifidobacterial-derived cell
wall treated mice at day 3 after influenza infection. Of note, IFN-λ has
been reported to restrict viral replication without inducing pro-
inflammatory responses or immunopathology [50-53]. Thus, the pro-
tective factor within the bifidobacterial cell wall may reduce type I
IFN damaging responses due to promoting appropriate type III IFNresponses for anti-viral defense, although this mechanism will need
to be further explored in future studies.
The bifidobacterial-derived cell wall fraction induced a dose-
dependent increase in surfactant protein D (SP-D). SP-D is an innate
sensor and contributor to anti-viral defense. SP-D has been reported
to inhibit viral entry into epithelial cells and enhances phagocytosis
and pulmonary clearance of influenza virus [54-56]. It acts, in part, by
binding to viral mannose-rich glycans [57-59]. SP-D mediates a range
of antiviral activities in vitro, including neutralization of virus infec-
tivity and inhibition of the enzymatic activity of the viral neuramini-
dase, and SP-D-deficient mice were more susceptible to infection
with highly glycosylated influenza viruses [56,57,59-62]. Thus, SP-D
may be an additional important component mediating the bifidobac-
terial-induced benefits within the lung.
Differences in illness severity to a specific viral infection are
thought to reflect variations in the host immune response. The cur-
rent study suggests that these host response features are significantly
influenced by exposure to certain microbes or their associated com-
ponents. Recent studies in viral infection models using BALB/C mice
Fig. 4. B. longum 35624-derived cell wall reduces lung cell death and vascular leakage.
BAL LDH (a) and albumin (b) levels were analysed at day 5 post-influenza innoculation in animals receiving vechicle control alone, those administered the bifidobacterial-
derived cell wall fraction starting 2 h before influenza inoculation (B. longum cell wall) or those animals administered the bifidobacterial-derived cell wall fraction starting 24 h after
influenza inoculation (B. longum cell wall therapeutic) or uninfected controls. Data are presented as box-and-whisker plots with the median values and maximum/minimum values
illustrated of 10 animals per group. *p < 0.05; **p < 0.01 (1-way ANOVA).
Fig. 5. B. longum 35624-derived cell wall alters the cytokine profile of BAL.
Heatmap representing increasing levels (blue to red) of the BAL cytokines, chemokines and surfactant protein D (SP-D) for each group at two time points (3 days or 5 days post
inoculation with influenza). Peak fold change in cytokine levels was normalized by dividing the sum of the mean of fold change observed in the vehicle group.
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Fig. 6. Time course profiles of surfactant protein D and cytokines in BAL from influenza infected mice.
Concentrations in BAL at days 3, 5 and 10 days post-viral innoculation for (a) IFN-λ2/3, (b) surfactant protein D (SP-D), (c) IFN-a, (d) IFN-b, (e) IFN-g (f) IP-10, (g) MCP-1, and (h)
IL-6 were determined by Multiplex assay. Data shown are mean § SEM results of 5 animals per group for each time point. *p < 0.05; ***p < 0.001 (2-way ANOVA).
D. Groeger et al. / EBioMedicine 60 (2020) 102981 9suggest that the relative timing of the type 1 IFN responses and maxi-
mal virus replication is a key determinant of outcome [63,64]. While
the dynamic nature of the cytokine and chemokine responses was
evident in the present study using BALB/C mice, it is particularlynoteworthy that the beneficial effect of intra-nasal bifidobacterial
treatment was evident regardless of whether it was administered
before or after the onset of infection, but optimal timing of adminis-
tration needs to be further defined.
Fig. 7. B. longum PB-VIRTM protects against lethal influenza infection.
(a) Survival was evaluated up to 10 days post inoculation (n = 5 animals per group). *p < 0.05 (log-rank Mantel-Cox test). (b) Viral load was measured at day 5 post-infection by
quantitative real-time PCR. Data are presented as box-and-whisker plots with the median values and maximum/minimum values illustrated (n = 5 animals per group). ***p < 0.01
(1-way ANOVA). (c) Macrophage counts in BAL fluid were compared at days 5 post innoculation. Data are presented as box-and-whisker plots with the median values and maxi-
mum/minimum values illustrated (n = 5 animals per group). **p < 0.01 (1-way ANOVA). (d) BAL albumin levels were analysed at day 5 post-influenza innoculation as determined
by ELISA. Data are presented as box-and-whisker plots with the median values and maximum/minimum values illustrated (n = 5 animals per group)..***p < 0.001 (1-way ANOVA).
Concentrations in BAL at day 5 post viral innoculation for (e) IFN-a, (f) IFN-b, and serum (g) SP-D were determined by Multiplex assay. Data are presented as box-and-whisker plots
with the median values and maximum/minimum values illustrated (n = 5 animals per group). *p < 0.05; **p < 0.01,. ****p < 0.0001 (1-way ANOVA).
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D. Groeger et al. / EBioMedicine 60 (2020) 102981 11Probiotic effects are most commonly considered in the context of
protection against bacterial infections and disturbances of the intesti-
nal microbiome, such as in irritable bowel syndrome [12,65], but our
results support the prospect of a role in prevention or treatment of
viral infections in the lung. Moreover, safety, ease of administration by
topical application and comparatively low cost, are particularly appeal-
ing. The encouraging results of intra-nasal administration of B. longum
PB-VIRTM, B. longum 35624 and its cell wall derived fraction in a model
of lethal murine influenza infection with the mouse adapted PR8
strain, suggests that this strategy should be examined in future human
studies, particularly against seasonal influenza infections. However,
optimal strain selection, product format and route of administration
for use in humans for this particular indication will require more
research including logistical as well biological considerations.
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